| [1] |
Moreno-Cubero E, del Arco RTS, Pena-Asensio J, et al. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?[J]. World J Gastroenterol,2018,24(17):1825-1838.
|
| [2] |
WHO. Global hepatitis report 2017:1-83.
URL
|
| [3] |
Collaborators GH. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017[J]. Lancet HIV,2019,6(12):e831-e859.
|
| [4] |
Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. EMBO J,1992,11(11):3887-3895.
|
| [5] |
Dermani FK, Samadi P, Rahmani G, et al. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy[J]. J Cell Physiol, 2019,234(2):1313-1325.
|
| [6] |
Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation[J]. J Immunol,2004,173(2):945-954.
|
| [7] |
Dai S, Jia R, Zhang X, et al. The PD-1/PD-Ls pathway and autoimmune diseases[J]. Cell Immunol,2014,290(1):72-79.
|
| [8] |
Zhang X, Schwartz JC, Guo X, et al. Structural and functional analysis of the costimulatory receptor programmed death-1[J]. Immunity,2004,20(3):337-347.
|
| [9] |
Saresella M, Rainone V, Al-Daghri NM, et al. The PD-1/PD-L1 pathway in human pathology[J]. Curr Mol Med,2012,12(3):259-267.
|
| [10] |
Shinohara T, Taniwaki M, Ishida Y, et al. Structure and chromosomal localization of the human PD-1 gene (PDCD1)[J]. Genomics,1994,23(3):704-706.
|
| [11] |
Gianchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity[J]. Autoimmun Rev,2013,12(11):1091-1100.
|
| [12] |
Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion[J]. Nat Med,1999,5(12):1365-1369.
|
| [13] |
Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity[J]. Annu Rev Immunol,2008,26:677-704.
|
| [14] |
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer,2012,12(4):252-264.
|
| [15] |
Hebeisen M, Baitsch L, Presotto D, et al. SHP-1 phosphatase activity counteracts increased T cell receptor affinity[J]. J Clin Invest,2013,123(3): 1044-1056.
|
| [16] |
Chikuma S, Terawaki S, Hayashi T, et al. PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo[J]. J Immunol,2009,182(11):6682-6689.
|
| [17] |
Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2[J]. J Exp Med,2012,209(6):1201-1217.
|
| [18] |
Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity[J]. Curr Top Microbiol Immunol,2011,350:17-37.
|
| [19] |
Baumeister SH, Freeman GJ, Dranoff G, et al. Coinhibitory pathways in immunotherapy for cancer[J]. Annu Rev Immunol,2016,34:539- 573.
|
| [20] |
Wherry EJ. T cell exhaustion[J]. Nat Immunol,2011,12(6):492- 499.
|
| [21] |
Buermann A, Romermann D, Baars W, et al. Inhibition of B-cell activation and antibody production by triggering inhibitory signals via the PD-1/PD-ligand pathway[J]. Xenotransplantation,2016,23(5):347- 356.
|
| [22] |
Bengsch B, Martin B, Thimme R. Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation[J]. J Hepatol,2014,61(6):1212-1219.
|
| [23] |
Raziorrouh B, Heeg M, Kurktschiev P, et al. Inhibitory phenotype of HBV-specific CD4+ T-cells is characterized by high PD-1 expression but absent coregulation of multiple inhibitory molecules[J]. PLoS One,2014,9(8):e105703.
|
| [24] |
Huang ZY, Xu P, Li JH, et al. Clinical significance of dynamics of programmed death ligand-1 expression on circulating CD14(+) monocytes and CD19(+) B cells with the progression of hepatitis B virus infection[J]. Viral Immunol,2017,30(3):224-231.
|
| [25] |
Salimzadeh L, Le Bert N, Dutertre CA, et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection[J]. J Clin Invest,2018,128(10):4573-4587.
|
| [26] |
Zhang Z, Zhang JY, Wherry EJ, et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B[J]. Gastroenterology,2008,134(7):1938-1949, e1-3.
|
| [27] |
Boni C, Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection[J]. J Virol,2007,81(8):4215-4225.
|
| [28] |
Fisicaro P, Valdatta C, Massari M, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B[J]. Gastroenterology,2010,138(2):682-693, e1-4.
|
| [29] |
Burton AR, Pallett LJ, McCoy LE, et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B[J]. J Clin Invest,2018,128(10):4588-4603.
|
| [30] |
Zhang E, Zhang X, Liu J, et al. The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection[J]. PLoS One,2011,6(10):e26196.
|
| [31] |
Liu J, Zhang E, Ma Z, et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection[J]. PLoS Pathog,2014,10(1):e1003856.
|
| [32] |
Gane E, Gaggar A, Nguyen A H, et al. A phase1 study evaluating anti-PD-1 treatment with or without GS-4774 in HBeAg negative chronic hepatitis B patients[J]. J Hepatol,2017,66(1):S26-S27.
|
| [33] |
Gane E, Verdon DJ, Brooks AE, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study[J]. J Hepatol,2019,71(5):900-907.
|
| [34] |
Barathan M, Mohamed R, Vadivelu J, et al. CD8+ T cells of chronic HCV-infected patients express multiple negative immune checkpoints following stimulation with HCV peptides[J]. Cell Immunol,2017,313:1-9.
|
| [35] |
Cho H, Kang H, Lee HH, et al. Programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) in viral hepatitis[J]. Int J Mol Sci,2017,18(7):1517.
|
| [36] |
Wang W, Tong Z, Zhong J, et al. Identification of IL-10-secreting CD8(+)CD28(-)PD-1(+) regulatory T cells associated with chronic hepatitis C virus infection[J]. Immunol Lett,2018,202:16-22.
|
| [37] |
Ojiro K, Qu X, Cho H, et al. Modulation of hepatitis C virus-specific CD8 effector T-cell function with antiviral effect in infectious hepatitis C virus coculture model[J]. J Virol,2017,91(10):e02129-16.
|
| [38] |
Fuller MJ, Callendret B, Zhu B, et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1) [J]. Proc Natl Acad Sci USA,2013,110(37):15001-15006.
|
| [39] |
Nakamoto N, Cho H, Shaked A, et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade[J]. PLoS Pathog,2009,5(2):e1000313.
|
| [40] |
Gardiner D, Lalezari J, Lawitz E, et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection[J]. PLoS One,2013,8(5):e63818.
|
| [41] |
Cox MA, Nechanitzky R and Mak TW. Check point inhibitors as therapies for infectious diseases[J]. Curr Opin Immunol,2017,48:61- 67.
|
| [42] |
Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction[J]. Nat Med,2006,12(10):1198-1202.
|
| [43] |
Chew GM, Fujita T, Webb GM, et al. TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection[J]. PLoS Pathog,2016,12(1):e1005349.
|
| [44] |
Ghiglione Y, Trifone C, Salido J, et al. PD-1 expression in HIV-specific CD8+ T-cells prior to antiretroviral therapy is associated with HIV persistence[J]. J Acquir Immune Defic Syndr,2018,80(1):1-6.
|
| [45] |
Hoang TN, Harper JL, Pino MC, et al. Bone marrow-derived CD4(+) T cells are depleted in SIV-infected macaques and contribute to the size of the replication competent reservoir on ART[J]. J Virol,2018,93(1):e01344-18.
|
| [46] |
Leon-Flores A, Del Rio Estrada PM, Alvarez-Garcia LX, et al. Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1(+) individuals[J]. Immunol Lett,2018,203:70-79.
|
| [47] |
Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression[J]. Nature,2006,443(7109):350-354.
|
| [48] |
Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8(+) T cell survival in HIV infection[J]. J Exp Med,2006,203(10):2281-2292.
|
| [49] |
Mylvaganam GH, Chea LS, Tharp GK, et al. Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV[J]. JCI Insight,2018,3(18):e122940.
|
| [50] |
Gill AL, Green SA, Abdullah S, et al. Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab)[J]. AIDS,2016,30(16):2487-2493.
|
| [51] |
Grabmeier-Pfistershammer K, Stecher C, Zettl M, et al. Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade[J]. Clin Immunol,2017,183:167-173.
|
| [52] |
Plachouri KM, Vryzaki E, Georgiou S. Cutaneous adverse eents of immune checkpoint inhibitors: A summarized overview[J]. Curr Drug Saf,2019,14(1):14-20.
|
| [53] |
Tanios GE, Doley PB, Munker R. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the FDA database and review[J]. Eur J Haematol,2019,102(2):157-162.
|
| [54] |
Nishino M, Ramaiya NH, Awad MM, et al. PD-1 Inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course[J]. Clin Cancer Res,2016,22(24):6051-6060.
|
| [55] |
Widmann G, Nguyen VA, Plaickner J, et al. Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy[J]. Curr Radiol Rep,2016,5(11):59.
|
| [56] |
Winer A, Bodor JN, Borghaei H. Identifying and managing the adverse effects of immune checkpoint blockade[J]. J Thorac Dis,2018,10(Suppl 3):S480-S489.
|
| [57] |
Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors[J]. Cancer Treat Rev,2016,44:51-60.
|
| [58] |
Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group[J]. J Immunother Cancer,2017,5(1):95.
|
| [59] |
Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens A systematic review and Meta-analysis[J]. JAMA Oncol,2018,4(2):173-182.
|
| [60] |
Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy[J]. Diabetes Care,2015,38(4):e55-e57.
|
| [61] |
Spain L, Walls G, Julve M, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature[J]. Ann Oncol,2017,28(2):377-385.
|
| [62] |
Williams TJ, Benavides DR, Patrice KA, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer[J]. JAMA Neurol,2016,73(8):928-933.
|